TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris.~* Must have a minimum of ≥ 25 non-inflammatory lesions and ≥ 20 inflammatory lesions and ≤ 2 nodulocystic lesions at baseline on the face.~* Must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the Investigator's Global Assessment.~Exclusion Criteria:~* Female subjects who are pregnant, nursing or planning to become pregnant during study participation.~* Have a history of hypersensitivity or allergy to tazarotene, retinoids and/or any of the study medication ingredients.~* Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Test (Type: EXPERIMENTAL): Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)
- Reference (Type: ACTIVE_COMPARATOR): TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Haemophilia A~* Body Mass Index (BMI) below 35 kg/m2~* History of a minimum 150 exposure days (EDs) to FVIII products (prophylaxis/prevention/surgery/on-demand)~Exclusion Criteria:~* Any history of FVIII inhibitors~* Surgery planned to occur during the trial~* Platelet count less than 50,000 platelets/microlitre (assessed by laboratory)~* Congenital or acquired coagulation disorders other than haemophilia A

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Esomeprazole for Treatment of GERD in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients' parents/guardians must provide written informed consent prior to the execution of any study-related procedures.~* Patients who are able to comprehend their involvement in a clinical study, including risks and benefits, (typically ≥6 years of age) must have assent documented by study personnel prior to any study-related procedures.~* Patients must be diagnosed with endoscopically proven GERD by the investigator during the screening period or have a previous (within 2 weeks prior to Visit 1) diagnosis of erosive esophagitis by endoscopy and are candidates for PPI therapy.~Exclusion Criteria:~* Patients who have used a proton pump inhibitor within 14 days prior to randomization, including over-the-counter omeprazole.~* Patients who have used any prescription or over-the-counter (OTC) treatment (other than proton pump inhibitors) for symptoms of GERD, such as histamine 2 receptor antagonists or prokinetics, within 72 hours prior to randomization.~* Patients with a known hypersensitivity, allergy, or intolerance to any component of esomeprazole or omeprazole.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 11 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of onychomycosis of at least one great toenail~* Percent Nail Involvement Score of the more severely affected great toenail (the Target Toenail) must be between 2 and 3 (25-75% of the nail unit).~* Length of Unaffected Part of the Target Toenail ≥2mm~* Direct microscopic examination with KOH that is positive for the hyphae associated with dermatophytes on the target toenail~* Subjects must have signed informed consent~* If the subject is woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control until the first menses after 60 days following the last dose of study medication.~Exclusion Criteria:~* Onychomycosis caused by Candida spp. without the presence of a dermatophyte~* Participation in a clinical trial for the systemic treatment of onychomycosis of the toenail within 24 weeks prior to Visit 1~* Use of systemic antifungals within 12 weeks prior to Visit 1~* Use of topical antifungal nail lacquer within 30 days prior to Visit 1~* Use of any other topical onychomycosis treatment on any toenail within 7 days prior to Visit 1~* Evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF~* Known liver disease or a history of liver toxicity with other drugs~* Use of systemic immunosuppressants

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Itraconazole tablets (Type: EXPERIMENTAL): Itraconazole 200 mg tablets
- Itraconazole capsules (Type: ACTIVE_COMPARATOR): Two Itraconazole 100 mg capsules were taken daily.
- Placebo tablets (Type: PLACEBO_COMPARATOR): The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Relapsed or refractory de novo classical Hodgkin lymphoma~* Participant may have failed to achieve a response to, progressed after, or be ineligible for autologous stem cell transplant (auto-SCT)~* Participant may have failed to achieve a response or progressed after treatment with brentuximab vedotin or may be brentuximab vedotin naïve~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Measurable disease~* Adequate organ function~Exclusion criteria:~* Diagnosis of immunosuppression or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication~* Prior monoclonal antibody within 4 weeks prior to study Day 1 or chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks prior to study Day 1~* Prior allogeneic hematopoietic stem cell transplantation~* Known clinically active central nervous system involvement~* Known additional malignancy that is progressing or requires active treatment~* Has a known history of Human Immunodeficiency Virus (HIV)~* Has known active Hepatitis B (HBV) or Hepatitis C (HCV)~* Active autoimmune disease requiring systemic treatment in past 2 years~* Has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle for up to 24 months.
- Cohort 2 (Type: EXPERIMENTAL): Participants with RRcHL who were unable to achieve CR or PR to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months.
- Cohort 3 (Type: EXPERIMENTAL): Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Only patients having signed the consent form regarding study information, data transfer and data use~* The patients suffer from idiopathic Parkinson's Disease (iPD) treated with a combination of L-dopa or another oral iPD drug and Neupro® for at least one month~* The patients require caregiver support documented as per medical records (e.g. based on German level of care intensity 1 or greater)~* The decision to prescribe Neupro® must have been made by the physician independent of his/her decision to include the patient in the study~Exclusion Criteria:~* Patients not fulfilling the inclusion criteria~* And according to Summary of Product Characteristics (SmPC): Hypersensitivity to the active substance or to any of the excipients, magnetic resonance tomography (MRT) or cardioversion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neupro® Treatment (Type: None): Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertension systolic blood pressure (SBP) \</= 160mm Hg and diastolic blood pressure (DBP): 90-105mm Hg~Exclusion Criteria:~* Pre-menopausal women~* patients currently taking more than two (2) blood pressure lowering medications~* Body Mas Index (BMI)\>40 kg/m2 (morbidly obese patients)~* History of Alcohol abuse (\<3 Years)~* History of diabetes,chronic kidney disease, Active liver disease, recent heart attack or stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- High BMI:MK-0736 2mg→Placebo (Type: EXPERIMENTAL): Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
- High BMI:MK-0736 7mg→Placebo (Type: EXPERIMENTAL): Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
- High BMI:MK-0916 6mg→MK-0916 6mg (Type: EXPERIMENTAL): Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
- High BMI:Placebo→Placebo (Type: PLACEBO_COMPARATOR): Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
- Low BMI:MK-0916 6mg→MK-0916 6mg (Type: EXPERIMENTAL): Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
- Low BMI:Placebo→Placebo (Type: PLACEBO_COMPARATOR): Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have bipolar I disorder (current episode manic or mixed), be treated with lithium or valproic acid, and have completed the a 12-week lead-in trial~Exclusion Criteria:~* Have an unstable medical condition or clinically significant laboratory abnormality.~* Have a primary diagnosis other than bipolar I disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asenapine (Type: ACTIVE_COMPARATOR): Asenapine
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≤ 75 years.~* ECOG ≤ 3.~* Morphologic Diagnosis of LPA (FAB M3 or variant M3). Those cases without typical morphology but with PML-RARα reordering also must be including.~* Genetic Diagnosis: t (15; 17) demonstrated by cariotipo conventional, FISH, PML-RARα reordering detected by RT-PCR or a pattern microspeckled demonstrated with antibody anti-PML (positive PGM3). Obvious, it will be had the result of these tests once initiated the treatment on the basis of a suspicion diagnoses morphologic~Exclusion Criteria:~* Age \>75 years (the treatment with this protocol can be considered individually)~* Absence of PML-Rare reordering.~* To have received previously some type of treatment for LPA, including chemotherapy or retinoides. The previous treatment with corticoids, hidroxiurea or leucoaféresis is not reason for exclusion.~* To have received chemotherapy or x-ray for the treatment of a disease vitiates previous.~* Associate Neoplasia.~* Serious psychiatric Disease.~* Seropositividad for VIH.~* Contraindication to receive intensive chemotherapy, specially antraciclinas.~* Sérica Creatinina ≥ 2,5 mg/dL (≥ 250 μmol/l).~* Bilirrubina, fosfatasa alkaline, or GOT \> 3 times the normal limit~* Test of positive pregnancy.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diabetes Prevention and Control in the Workplace: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult employees of Onondaga County~Exclusion Criteria:~* Not an employee of Onondaga County~* Less than age 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A, 1 (Type: EXPERIMENTAL): Intervention: Immediate 3 month program
- A, 2 (Type: NO_INTERVENTION): Wait-List Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30-65~* An accelerated plethysmograph (APG) type (biological age of arteries) of D, E, F or G and/or a high density lipoprotein (HDL) to total cholesterol (TC) ratio of ≤24 percent~Exclusion Criteria:~* Have used prescription cholesterol or blood pressure medication in the last 3 months~* Perform more then 150 minutes of moderate to rigorous activity per week~* Pregnant or planning on getting pregnant during the study period

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Participants in the experimental group will be given 1 serving (10g) of Cardioflex each day.
- Control Group (Type: PLACEBO_COMPARATOR): Participants in the control group will be given a flavoured 10g placebo that looks and tastes exactly like Cardioflex.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients at least 18 years of age~* CHC infection, genotype 1~* unable to tolerate or not responsive to PEG-Intron + ribavirin therapy after 12 weeks of treatment~* use of 2 forms of contraception during the study in both men and women~Exclusion Criteria:~* women who are pregnant or breast-feeding~* medical condition associated with chronic liver disease (eg, hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures)~* patients with decompensated cirrhosis~* patients receiving any systemic antiviral therapy or investigational drug, other than PEG-Intron + ribavirin, 24 weeks prior to the first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-Responders (Type: EXPERIMENTAL): Participants will receive Pegasys 180 micro grams (µg or mcg) subcutaneously (SC) once a week and ribavirin 1000 or 1200 milligrams per day \[(mg/day), \< or \>=75 kilogram (Kg) body weight, respectively\], orally in divided doses for 60 weeks.
- Non-Tolerators (Type: EXPERIMENTAL): Participants will receive Pegasys 180 µg subcutaneously (SC) once a week and ribavirin 1000 or 1200 mg/day (\< or \>=75 kg body weight, respectively) orally in divided doses for 36 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feeding Malnourished Children Different Types of Fatty Acids to Promote Neurocognitive Development

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 6-59 months~* An acceptable appetite defined by the ability to consume 30 grams RUTF within 20 minutes~* Mid Upper Arm Circumference \<11.5 cm, weight-for-height z-score \< -3, or bilateral pitting edema on the dorsum of the feet~Exclusion Criteria:~* Participation in any other ongoing study or supplementary feeding program~* Children with a chronic medical condition, including cerebral palsy, static encephalopathy, congenital heart disease, gastrointestinal disease, or peanut allergy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Conventional RUTF (S-RUTF) (Type: ACTIVE_COMPARATOR): This is the control group for the study, which will receive the international standard of care therapeutic food. S-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.
- High oleic RUTF (HO-RUTF) (Type: EXPERIMENTAL): The treatment provided to children randomized to this arm of the study includes nutritional content comparable to S-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.
- DHA-supplemented HO-RUTF (D-HO-RUTF) (Type: EXPERIMENTAL): The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/=18 years of age~* moderate to severe rheumatoid arthritis of \>/=6 months duration~* synovitis (swollen and tender joint) in the wrist of the dominant hand~* non-biologic DMARDs at stable dose for \>/=12 weeks prior to baseline~* oral corticosteroids at stable dose for at least 25 out of 28 days prior to baseline~Exclusion Criteria:~* rheumatic autoimmune disease other than RA~* history of or current inflammatory joint disease other than RA~* functional class IV (ACR classification)~* intraarticular or parenteral corticosteroids within 6 weeks prior to baseline~* previous treatment with a biologic agent for RA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete